Panel discussion

Antibody-Drug Conjugates (ADCs) are currently among the most promising drug classes in oncology due to their ability to deliver cytotoxins to specific tumor sites, combining the selectivity of antibodies and the efficacy of chemotherapeutic drugs. With the approval of trastuzumab deruxtecan (Enhertu) in 2019, we have been witnessing the soaring numbers of both preclinical and clinical ADC assets as well as a number of eye-catching investments and licensing deals in this field. What could be the development strategies for the next generation of ADCs ? What are the potentials on other bioconjugates other than typical ADCs (i.e. XDC)? Can the therapeutic areas be expanded beyond oncology? This panel would like to explore on those topics.